- You can view the full Novartis Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Stocks ended higher on Tuesday.
Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.